Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HCM3

News Conference News AHA 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

November 11, 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

November 11, 2023

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

CTA Doesn’t Add Value in At-Risk Patients Thought to Have ACS

News Conference News AHA 2020

CTA Doesn’t Add Value in At-Risk Patients Thought to Have ACS

November 20, 2020

One in Five Patients Admitted With COVID-19 Die in the Hospital

News Conference News AHA 2020

One in Five Patients Admitted With COVID-19 Die in the Hospital

Michael O'Riordan

November 20, 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

November 15, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

News Conference News AHA 2020

OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

November 14, 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.